Drug intelligence / Profile preview

norepinephrine (Centurion Pharma)

Development stage: Preclinical
Lead developer: Centurion
Modality: Small Molecules
Administration: Subcutaneous, Intramuscular

Overview

CNT-EMG-03 is a value-added formulation of norepinephrine (noradrenaline) being developed by Centurion as a self-injection system (auto-injector). While norepinephrine is traditionally administered via intravenous infusion in hospital settings to treat acute hypotension and shock, this drug-device combination is designed for rapid, intramuscular or subcutaneous administration in emergency scenarios. As a potent alpha-1, alpha-2, and beta-1 adrenergic receptor agonist, norepinephrine induces peripheral vasoconstriction and increases cardiac output, making it a critical intervention for maintaining blood pressure in life-threatening cardiovascular conditions.

Other names: noradrenaline

Targets

ADRA1A (α1A)ADRA2A (α2A)ADRB1 (β1)

Beyond the preview

Go deeper on norepinephrine (Centurion Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on norepinephrine (Centurion Pharma).